AHA research links energy drinks and stimulants to cardiac events
Published November 3, 2026 · Updated November 3, 2026 · 3 sources
Preliminary AHA research reviewing FDA reports links energy drinks and stimulant supplements to serious heart events in young adults. Market data included.
The exposed companies and what ATLAS says about each
Price change between the last close before the event and the latest available close. It is a coincidence in time, not a cause-and-effect relationship.
Energy drink maker whose core products are directly named in the cardiac risk research. · Consumer Defensive
Monster Beverage makes energy drinks, the product category directly named in the cardiac risk research. Its close was $48.02 on November 2 and $48.02 on November 3, a change of down 0.00%, which is a coincidence in time and not evidence of cause. The company's next earnings report is November 5 after the close, with estimated EPS of 0.30.
Price between closes
$48.02 → $48.02Close of November 2 and November 3
Fair value (ATLAS)
$56.46Fair range: $45.27 to $81.50The price ($48.02) is 15.0% below that figure.
Chance of a rise in 1 month
52%Probability of closing higher than today within 21 sessions.Normal range: half of the scenarios end between $46.19 and $50.25; 9 in 10, between $42.87 and $54.15.
Beverage company with energy drink brands such as Rockstar, exposed to scrutiny of the category. · Consumer Defensive
PepsiCo is a beverage company with energy drink brands such as Rockstar; it is included for its activity in the sector, not because the event affects it. Its close was $140.42 on November 2 and $140.42 on November 3, a change of down 0.00%. Its dividend yield is 4.14%.
Price between closes
$140.42 → $140.42Close of November 2 and November 3
Fair value (ATLAS)
$188.64Fair range: $152.75 to $232.97The price ($140.42) is 25.6% below that figure.
Chance of a rise in 1 month
52%Probability of closing higher than today within 21 sessions.Normal range: half of the scenarios end between $135.25 and $146.81; 9 in 10, between $125.76 and $157.88.
S&P 500 between the same closes (November 2 and November 3): 7,541.40 → 7,564.49 points, +0.31%.
What happened
Preliminary research to be presented at the American Heart Association's Scientific Sessions 2026 found that caffeinated energy drinks and stimulant supplements appeared disproportionately often in FDA reports of serious cardiovascular events, especially among adults ages 18 to 34 [1]. The beverage makers Monster Beverage and PepsiCo are included as context for the category; their share prices were unchanged between the November 2 and November 3 closes.
The research reviewed more than 28,000 adverse-event reports to the FDA over eight years, 2017-2025. Caffeinated energy drinks and stimulant supplements were linked to serious heart conditions far more often than other products, including cardiac arrest and heart attacks [1]. The work is described as independent and preliminary [1].
The findings are to be presented at the meeting in Chicago, Nov. 6-9 [1]. NBC News reported that adverse events related to the heart were far more common for energy drinks and stimulant supplements than for other FDA-regulated products [3].
The American Heart Association release says sales of caffeinated energy drinks have more than doubled over the past decade, reaching over $20 billion in 2024. It also cites a 2026 AHA Scientific Statement saying up to 400 mg of caffeine per day is generally safe for most adults [1].
The release adds that some energy drinks contain as much as 3 times more caffeine per fluid ounce than brewed coffee, and some pre-workout supplements more than 12 times as much [1]. A Seeking Alpha headline says energy drinks face fresh scrutiny over potential cardiac risks [2].
What ATLAS data show
ATLAS model estimates put Monster Beverage's fair value at $56.46, within a range of $45.27 to $81.50, with the price 14.96% below that value. For PepsiCo the estimate is $188.64, within a range of $152.75 to $232.97, with the price 25.56% below it. These are model estimates, not promises, and they do not indicate what prices will do. For comparison, the S&P 500 rose 0.31% between the November 2 and November 3 closes, from 7,541.40 to 7,564.49 points.
Two share prices moving, or not moving, around the same dates as a news event does not show that one caused the other. The figures come from market closes and may change, and the research is preliminary.
What you get with ATLAS
Fair value of each company, with its range, against today's price.
Chance of a rise in 1 month and the normal price range, from a calibrated model.
Earnings: next date, estimated EPS and surprise history.
Dividends and alerts by email when a company reports.
In more than 28,000 FDA adverse-event reports from 2017-2025, energy drinks and stimulant supplements appeared disproportionately often in serious cardiovascular events, especially among adults ages 18 to 34 [1].
Has the research been presented yet?
It is to be presented at the American Heart Association's Scientific Sessions 2026 in Chicago, Nov. 6-9, and is described as preliminary [1].
Did Monster Beverage's share price change?
Its close was $48.02 on both November 2 and November 3, a change of down 0.00%.
Closing prices, fair value, probabilities, earnings and dividends: ATLAS own data as of November 3, 2026. How we calculate fair value.
Information, not advice. This content is informational and is not an investment recommendation or an offer to buy or sell securities. ATLAS estimates come from statistical models using public data, can be wrong, and past performance does not guarantee future results. Disclaimer
ATLAS Signals
ATLAS Signals, every week
The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.
By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy
ATLAS